DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by LRI Investments LLC

LRI Investments LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 225.0% during the third quarter, HoldingsChannel reports. The institutional investor owned 8,454 shares of the medical device company’s stock after acquiring an additional 5,853 shares during the quarter. LRI Investments LLC’s holdings in DexCom were worth $567,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Blue Whale Capital LLP lifted its position in shares of DexCom by 91.9% during the third quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock worth $15,821,000 after purchasing an additional 113,000 shares in the last quarter. Taylor Frigon Capital Management LLC lifted its position in shares of DexCom by 51.6% during the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock worth $2,182,000 after purchasing an additional 11,075 shares in the last quarter. Brooktree Capital Management acquired a new position in shares of DexCom during the third quarter worth $683,000. National Pension Service lifted its position in shares of DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after purchasing an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new position in shares of DexCom during the third quarter worth $650,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of recent research reports. JPMorgan Chase & Co. boosted their target price on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research report on Friday, October 25th. Wells Fargo & Company upped their price target on shares of DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Canaccord Genuity Group upped their price target on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a report on Monday. Sanford C. Bernstein upped their price target on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $101.88.

DexCom Stock Up 0.9 %

DexCom stock opened at $78.41 on Tuesday. The company has a 50-day simple moving average of $72.77 and a 200-day simple moving average of $85.41. The firm has a market capitalization of $30.63 billion, a P/E ratio of 46.95, a P/E/G ratio of 2.38 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00.

Insider Transactions at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.